{"nctId":"NCT00172185","briefTitle":"Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)","startDateStruct":{"date":"2005-01-10","type":"ACTUAL"},"conditions":["Short Bowel Syndrome"],"count":65,"armGroups":[{"label":"teduglutide 0.05 mg/kg/d","type":"EXPERIMENTAL","interventionNames":["Drug: teduglutide 0.05 mg/kg/d"]},{"label":"teduglutide 0.10 mg/kg/d","type":"EXPERIMENTAL","interventionNames":["Drug: teduglutide 0.10 mg/kg/d"]}],"interventions":[{"name":"teduglutide 0.05 mg/kg/d","otherNames":["GATTEX"]},{"name":"teduglutide 0.10 mg/kg/d","otherNames":["GATTEX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAt dosing week 24 of protocol CL0600-004 (NCT00081458), subjects will be reviewed for their participation in this study.\n\nSubjects who meet all of the following criteria can be enrolled in this study:\n\n* Signed and dated informed consent form (ICF) to participate before any study-related procedures are performed\n* Completion of protocol CL0600-004 (NCT00081458)\n\nExclusion Criteria:\n\n* History of cancer or clinically significant lymphoproliferative disease with fewer than 5 years documented disease-free state\n* History of alcohol or drug abuse (within previous year)\n* Prior use of native glucagon-like peptide 2 (GLP-2) within 3 months of screening visit\n* Pregnant or lactating women\n* Any condition or circumstance, which in the investigator's opinion would put the subject at any undue risk, prevent completion of the study, or interfere with analysis of the study results","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Achieving a 20% Reduction at Week 28","description":"For those subjects who received teduglutide (0.05 or 0.10 mg dose) in Study 004 and the same in Study 005, Parenteral Nutrition (PN) Use at Week 28 was compared to the Baseline Visit of Study 004 to calculate the 20% reduction in PN Use. For those subjects who received placebo in Study 004 and either teduglutide 0.05 or 0.10 mg dose in Study 005, PN Use at Week 28 was compared to the use of PN at Week 24 of Study 004 to calculate the 20% reduction in PN Use.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use","description":"Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use (Responder Status is Yes or No)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":6},"commonTop":["Headache","Abdominal pain","Skin and subcutaneous tissue disorder","Nausea","Nasopharyngitis"]}}}